mardi 10 avril 2018

Onco Actu du 10 avril 2018

1. Biologie

Blood flow is a major influence on tumour cell metastasis [ecancernews]

Cancer cure hope for endangered Tasmanian devil [The Telegraph]

1.1 Biologie - Gènes

Researchers discover 40 genes involved in early development of myeloma [Institute of Cancer Research]

2.4 Etiologie - Portables, ondes e-m

Conspiratorial fear mongering about cell phones and cancer, courtesy of The Nation [Respectful Insolence]

3.1 Prévention - Tabac

Study: Stop-smoking drugs Chantix, Zyban pose no heart risks [STAT]

4. Dépistage, diagnostic et pronostic

Patients aged over 60 who lose weight 'should be tested for cancer' [The Telegraph]

4.10 Dép., diag. & prono. - Poumon

The importance of staging lung cancer consistently and correctly worldwide [The Cancer Letter]

4.2 Dép., diag. & prono. - Génome

Consumers don’t need experts to interpret 23andMe genetic risk reports [STAT]

4.5 Dép., diag. & prono. - Colorectal

Interactive App Improves Colorectal Cancer Screening Rates [NCI]

5. Traitements

Looking to the future of oncology [Pharmafile]

5.12.10 Immunothérapies - Fusions et acquisitions

Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital' [Forbes]

5.12.2 Immunothérapies - CAR-T

China’s CAR-T Therapy Race [PharmExec]

5.12.3 Immunothérapies-combinaisons

Incyte Cancer Drug Flop Is Costly and Likely to Be Duplicated [Bloomberg]

IDO Inhibitors Hit a Wall [In the Pipeline]

5.12.4 Immunothérapies - Essais

Merck's Keytruda upends lung cancer market with latest survival win [FiercePharma]

Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy [EndPoints]

KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells [Merck]

Merck's Keytruda meets main goal in pivotal lung cancer trial [Reuters]

5.12.5 Immunothérapies - Pharma

Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies [EndPoints]

Immunomedics poaches AstraZeneca I-O executive as new research chief [FierceBiotech]

5.3.4 Traitements - AMM (FDA, EMA,...)

Clovis' Rubraca joins the 'three-horse' PARP race in recurrent ovarian cancer [FiercePharma]

5.4 Traitements - Economie

In a win for Roche, cost gatekeepers change tune to back Tecentriq in lung cancer [FiercePharma]

Tecentriq third time lucky after NICE nod in lung cancer [Pharmafile]

6. Lutte contre les cancers

Theresa May unveils war on prostate cancer[The Telegraph]

Theresa May launches £75m drive against prostate cancer [The Guardian]

6.10 Politiques

China asserts firm grip on research data [Science]

6.3 Associations/Fondations

Manocherian: We have been unapologetic in advocating for 10% annual increases to NIH [The Cancer Letter]

How Jed Manocherian’s stealth campaign for NIH was outed by its own success [The Cancer Letter]

6.4 Médico-éco

How to reduce health care costs? Experts say lots of ideas, few successes [STAT]

Cancer drug choices tied to drugmaker payouts to doctors [Reuters]